Arrowsmith v. United States (In re Health Diagnostic Laboratory, Inc.)

578 B.R. 552
CourtUnited States Bankruptcy Court, E.D. Virginia
DecidedDecember 6, 2017
DocketCase No. 15-32919 (Jointly Administered); AP No. 17-04300
StatusPublished
Cited by2 cases

This text of 578 B.R. 552 (Arrowsmith v. United States (In re Health Diagnostic Laboratory, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Arrowsmith v. United States (In re Health Diagnostic Laboratory, Inc.), 578 B.R. 552 (Va. 2017).

Opinion

MEMORANDUM OPINION

Kevin R. Huennekens, UNITED STATES BANKRUPTCY JUDGE

The Court must decide in this adversary proceeding whether subchapter S corporation status (“S corporation status”) under Title 26 of the United States Code (the “Tax Code”)1 is considered “property” for the purposes of 11 U.S.C. §§ 544(b), 548. A hearing on that issue was held on November 30, 2017 (the “Hearing”), at which time the Court took the matter under advisement. For the reasons set forth below, the Court holds that S corporation status is not “property” for the purposes of 11 U.S.C. §§ 544(b), 548.

Jurisdiction and Venue

The Court has subject matter jurisdiction over this adversary proceeding pursuant to 28 U.S.C. §§ 157 and 1334, and the general order of reference from the United States District Court for the Eastern District of Virginia dated August 15, 1984. This is a core proceeding under 28 U.S.C. § 157(b). Venue is appropriate in this Court pursuant to 28 U.S.C. §§ 1408 and 1409.

Background and Procedural History

Health Diagnostic Laboratory, Inc. (“HDL”) was a privately held company based in Richmond, Virginia, that offered clinical laboratory services to physicians around the country. Under HDL’s business model, HDL processed blood tests it received from physicians and tested bio-markers for the indication of risk for cardiovascular disease, diabetes, and other illnesses. Afterwards, HDL would reimburse the referring physicians for the costs associated with collecting, processing, and handling the blood samples that they had sent to HDL for testing. In January of 2013, the United States Department of Justice (“DOJ”) and United States Department of Health and Human Services’ Office of Inspector General (“HHS OIG”) commenced an investigation into HDL in connection with HDL’s business practices including its payment of process and handling fees to the referring physicians as potential violations of the federal anti-kickback statute. HHS OIG issued a special fraud alert on June 25, 2014, advising that the payment of processing and handling fees to referring physicians could violate certain federal anti-kickback laws.

After the special fraud alert, negative publicity and lawsuits ensued. In April 2015, HDL agreed to a multi-million dollar settlement for alleged violations of the federal False Claims Act along with a corresponding corporate integrity agreement with HHS OIG. By that time, HDL’s relationship with its prepetition secured lender, Branch Banking and Trust Company (“BB <& T”), had become severely strained. HDL eventually defaulted under its BB & T loan facilities. In response, BB & T discontinued HDL’s borrowing ability and cut off HDL’s access to its existing accounts. With no ability to access its cash and with no alternative sources of financing immediately available, HDL was forced to file for protection under chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”).2

On June 7, 2015 (the “Petition Date”), HDL, Central Medical Laboratory, LLC, and Integrated Health Leaders, LLC (the “Debtors”) commenced bankruptcy cases (the “Bankruptcy Cases”) by each filing a separate voluntary petition for relief under chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Virginia (the “Court”).3 On June 16, 2015, the United States Trustee for the Eastern District of Virginia appointed a statutory committee of unsecured creditors in accordance with section 1102 of the Bankruptcy Code, (the “Committee”).

HDL’s Corporate and Tax Structure

As of the Petition Date, HDL had a four-member Board of Directors (the “Board"), which included Noel L, Bartlett, Robert S. Galen, Joseph P. McConnell, and George Russell Warnick. HDL had 19 shareholders who each owned various percentages of stock.4 Due to its corporate and shareholder attributes, HDL had the capacity to qualify as a “small business corporation” as defined by 26 U.S.C. § 1361(b).

On or about February 16, 2009, HDL filed an election to be classified as an S corporation under 26 U.S.C. § 1362, pursuant to unanimous shareholder consent as required by 26 U.S.C. § 1362(a)(2). Correspondingly, HDL filed S corporation elections with the State of New York Department of Taxation and Finance, the State of Arkansas Department of Finance and Administration, and the State of Mississippi Department of Revenue. Every other state where HDL did business either accepted the federal S corporation status election or did not recognize S corporation status.5

In accordance with Section 12(b) of the HDL Shareholders’ Agreement, HDL made distributions to its shareholders as means to reimburse them for HDL’s pass-through tax liability.6 HDL also made direct payments to the Internal Revenue Service (the “IRS”) and the State Taxing Authorities on behalf of the shareholders. Every year, HDL filed IRS form 1120S, which included a schedule K-1 for each shareholder (“Schedule K-1”) as it was required to do by section 6037(c)(1) of the Tax Code. HDL submitted corresponding forms to the State Taxing Authorities. Personally, the shareholders included on their individual tax returns the income, deductions, credits and other items displayed on the Schedules K-1.7

On January 1, 2015, HDL filed a Notice of Termination of HDL’s S corporation status with the IRS and the State Taxing Authorities. As required by federal law, a majority of HDL’s shareholders had voted in favor of revoking HDL’s S corporation status. Consequently, as of the Petition Date, HDL was subject to C corporation tax.

Bankruptcy Proceedings

On September 17, 2015, the Court entered an order (the “Sale Order”), which authorized the sale of substantially all of the Debtors’ assets to True Health Diagnostics, LLC (“True Health”) under the terms of an Asset Purchase Agreement (“APA”),8 On September 29, 2015, True Health acquired substantially all of the Debtors’ operating assets. On May 12, 2016, the Court entered an order (the “Confirmation Order”),9 which confirmed the Debtors’ Modified Second Amended Plan of Liquidation (the “Plan”).10 The HDL Liquidating Trust was formed pursuant the terms of the Plan on the Effective Date.11

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Callahan(76), Jr v. Decker
W.D. Virginia, 2020
Finley Grp. v. Roselli (In re RedF Mktg., LLC)
589 B.R. 534 (W.D. North Carolina, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
578 B.R. 552, Counsel Stack Legal Research, https://law.counselstack.com/opinion/arrowsmith-v-united-states-in-re-health-diagnostic-laboratory-inc-vaeb-2017.